Individualized and Agile Therapies
Chemical drugs that have been the primary disease control weapons over the last 100 years are being rendered ineffective by growing drug resistance in tumors. In addition, with our deepening understanding of cellular and molecular disease pathways, it has become clear that
a “one size fits all” approach cannot be effective across the general population.
Despite its tremendous promise, personalized medicine as it is practiced today has its own inherent limitations, particularly when it comes to the treatment of cancer. There is growing concern about whether the benefits of personalized cancer medicines outweigh their very high costs.
Tumor cells are highly heterogeneous, and it is unlikely that any single targeted medicine or protocol would be able to provide a total cure or long-term remission. In addition, cancer cells are known to develop resistance to medicines that target a specific pathway.
Clinical studies that have evaluated the impact of personalized cancer medicines have not shown conclusive results. The SHIVA trial, for example, which screened 741 patients with metastatic solid tumors, showed no significant difference in the primary end point (progression-free survival) between traditional therapies and genotype-matched drugs.
The current model of drug development is not viable over the long-term. Next-generation drugs take years to develop, are of limited effectiveness, are often very expensive, and are doomed to becoming obsolete as highly-adaptive cells develop resistance to the drug’s mechanism of action.
Aummune is developing a novel, groundbreaking strategy and technology to meet the critical, unmet need for truly individualized and agile therapeutic treatments.
The Aummune Therapy
Visit us soon...
Caution: Investigational Technology. Not yet approved by Federal (or United States) Law to Clinical Use.